Using Genomic and Transcriptome Analyses to Identify the Role of the Oxidative Stress Pathway in Renal Clear Cell Carcinoma and Its Potential Therapeutic Significance

被引：9
作者：
Che X. [1 ]
Qi X. [1 ]
Xu Y. [2 ]
Wang Q. [1 ]
Wu G. [1 ]
机构：
[1] Department of Urology, The First Affiliated Hospital of Dalian Medical University, Dalian
[2] Department of Endocrine and Breast Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing
来源：
Oxidative Medicine and Cellular Longevity | 2021年 / 2021卷
关键词：
Cell death;
D O I：
10.1155/2021/5561124
中图分类号：
学科分类号：
摘要：
Oxidative stress (OS) refers to endogenous and/or exogenous stimulation when the balance between oxidation and antioxidants in the body is disrupted, resulting in excessive production of free radicals. Excessive free radicals exert a series of negative effects on the body, which can result in the oxidation of and infliction of damage on biological molecules and further cause cell death and tissue damage, which are related to many pathological processes. Pathways related to OS have always been the focus of medical research. Several studies are being conducted to develop strategies to treat cancer by exploring the OS pathways. Therefore, this study is aimed at determining the correlation between the OS pathway and kidney renal clear cell carcinoma (KIRC) through bioinformatics analysis, at proving the effect of common anticancer drugs on the OS pathway, and at constructing a prognosis model of patients with KIRC based on several genes with the strongest correlation between the OS pathway and KIRC. We first collected and analyzed gene expression and clinical information of related patients through TCGA database. Then, we divided the samples into three clusters according to their gene expression levels obtained through cluster analysis. Using these three clusters, we performed GDSC drug analysis and GSEA analysis and examined the correlation among the OS pathway, histone modification, and immune cell infiltration. We also analyzed the response of anti-PD-1 and anti-CTLA-4 to the OS pathway. Thereafter, we used LASSO regression to select the most suitable nine genes, combined with the clinicopathological characteristics to establish the prognosis model of patients with KIRC, and verified the scientific precision of the model. Finally, tumor mutational burden was calculated to verify whether patients would benefit from immunotherapy. The results of this study may provide a reference for the establishment of treatment strategies for patients with KIRC. © 2021 Xiangyu Che et al.
引用
收藏
相关论文
共 45 条
  • [1] Prasad S., Gupta S.C., Tyagi A.K., Reactive oxygen species (ROS) and cancer: Role of antioxidative nutraceuticals, Cancer Letters, 387, pp. 95-105, (2017)
  • [2] Li R., Trush M., Trush M.A., Defining ROS in biology and medicine, Reactive Oxygen Species, 1, 1, pp. 9-21, (2016)
  • [3] Sies H., Oxidative stress: A concept in redox biology and medicine, Redox Biology, 4, pp. 180-183, (2015)
  • [4] He F., Ru X., Wen T., NRF2, a transcription factor for stress response and beyond, International Journal of Molecular Sciences, 21, 13, (2020)
  • [5] Battino M., Giampieri F., Pistollato F., Sureda A., De Oliveira M.R., Pittala V., Fallarino F., Nabavi S.F., Atanasov A.G., Nabavi S.M., Nrf2 as regulator of innate immunity: A molecular Swiss army knife!, Biotechnology Advances, 36, 2, pp. 358-370, (2018)
  • [6] Lin X., Bai D., Wei Z., Zhang Y., Huang Y., Deng H., Huang X., Curcumin attenuates oxidative stress in RAW264.7 cells by increasing the activity of antioxidant enzymes and activating the Nrf2-Keap1 pathway, PLoS One, 14, 5, ARTICLE E0216711, (2019)
  • [7] Done A.J., Traustadottir T., Nrf2 mediates redox adaptations to exercise, Redox Biology, 10, pp. 191-199, (2016)
  • [8] Taguchi K., Yamamoto M., The KEAP1-NRF2 system in cancer, Frontiers in Oncology, 7, (2017)
  • [9] Moloney J.N., Cotter T.G., ROS signalling in the biology of cancer, Seminars in Cell & Developmental Biology, 80, pp. 50-64, (2018)
  • [10] Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A., Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA: A Cancer Journal for Clinicians, 68, 6, pp. 394-424, (2018)
12345